These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 11912373)

  • 1. A single 24-hour urine collection is inadequate for the medical evaluation of nephrolithiasis.
    Parks JH; Goldfisher E; Asplin JR; Coe FL
    J Urol; 2002 Apr; 167(4):1607-12. PubMed ID: 11912373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adequacy of a single stone risk analysis in the medical evaluation of urolithiasis.
    Pak CY; Peterson R; Poindexter JR
    J Urol; 2001 Feb; 165(2):378-81. PubMed ID: 11176377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adequacy of a single 24-hour urine collection for metabolic evaluation of recurrent nephrolithiasis.
    Castle SM; Cooperberg MR; Sadetsky N; Eisner BH; Stoller ML
    J Urol; 2010 Aug; 184(2):579-83. PubMed ID: 20639021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical reduction of stone risk in a network of treatment centers compared to a research clinic.
    Lingeman J; Mardis H; Kahnoski R; Goldfarb DS; Lacy S; Grasso M; Scheinman SJ; Parks JH; Asplin JR; Coe FL
    J Urol; 1998 Nov; 160(5):1629-34. PubMed ID: 9783920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of metabolic evaluation and medical treatment for calcium nephrolithiasis in a private urological practice.
    Mardis HK; Parks JH; Muller G; Ganzel K; Coe FL
    J Urol; 2004 Jan; 171(1):85-8. PubMed ID: 14665850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spot urine samples for the metabolic evaluation of urolithiasis patients.
    Strohmaier WL; Hoelz KJ; Bichler KH
    Eur Urol; 1997; 32(3):294-300. PubMed ID: 9358216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the kidney stone patient.
    Asplin JR
    Semin Nephrol; 2008 Mar; 28(2):99-110. PubMed ID: 18359391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pediatric urinary stone disease--does age matter?
    Kalorin CM; Zabinski A; Okpareke I; White M; Kogan BA
    J Urol; 2009 May; 181(5):2267-71; discussion 2271. PubMed ID: 19296968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients with primary hyperparathyroidism--why do some form stones?
    Berger AD; Wu W; Eisner BH; Cooperberg MR; Duh QY; Stoller ML
    J Urol; 2009 May; 181(5):2141-5. PubMed ID: 19296981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lithogenic risk factors in the morbidly obese population.
    Duffey BG; Pedro RN; Kriedberg C; Weiland D; Melquist J; Ikramuddin S; Kellogg T; Makhlouf AA; Monga M
    J Urol; 2008 Apr; 179(4):1401-6. PubMed ID: 18289566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in urinary stone risk factors in hypocitraturic calcium oxalate stone formers treated with dietary sodium supplementation.
    Stoller ML; Chi T; Eisner BH; Shami G; Gentle DL
    J Urol; 2009 Mar; 181(3):1140-4. PubMed ID: 19152919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary metabolic evaluations in solitary and recurrent stone forming children.
    DeFoor W; Minevich E; Jackson E; Reddy P; Clark C; Sheldon C; Asplin J
    J Urol; 2008 Jun; 179(6):2369-72. PubMed ID: 18433777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced renal function and benefits of treatment in cystinuria vs other forms of nephrolithiasis.
    Worcester EM; Coe FL; Evan AP; Parks JH
    BJU Int; 2006 Jun; 97(6):1285-90. PubMed ID: 16686727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary reference values for stone risk factors in children.
    Borawski KM; Sur RL; Miller OF; Pak CY; Preminger GM; Kolon TF
    J Urol; 2008 Jan; 179(1):290-4; discussion 294. PubMed ID: 18006021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic abnormalities associated with calyceal diverticular stones.
    Auge BK; Maloney ME; Mathias BJ; Pietrow PK; Preminger GM
    BJU Int; 2006 May; 97(5):1053-6. PubMed ID: 16643491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The diagnostic value of the phosphate levels in serum and 24-hour urine samples in patients with recurrent renal stone disease.
    Müezzinoğlu T; Gümüş B; Sener E; Ari Z; Büyüksu C
    Scand J Urol Nephrol; 2002; 36(5):368-72. PubMed ID: 12487742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urine composition in type 2 diabetes: predisposition to uric acid nephrolithiasis.
    Cameron MA; Maalouf NM; Adams-Huet B; Moe OW; Sakhaee K
    J Am Soc Nephrol; 2006 May; 17(5):1422-8. PubMed ID: 16597681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient adherence to long-term medical treatment of kidney stones.
    Parks JH; Asplin JR; Coe FL
    J Urol; 2001 Dec; 166(6):2057-60. PubMed ID: 11696706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison between lemonade and potassium citrate and impact on urine pH and 24-hour urine parameters in patients with kidney stone formation.
    Koff SG; Paquette EL; Cullen J; Gancarczyk KK; Tucciarone PR; Schenkman NS
    Urology; 2007 Jun; 69(6):1013-6. PubMed ID: 17572176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [LithoRisk: A software for calculating and visualising nephrolithiasis risk profiles].
    Marangella M; Petrarulo M; Daniele PG; Sammartano S
    G Ital Nefrol; 2002; 19(6):693-8. PubMed ID: 12508173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.